The patent in question protects “respiratory virus vaccines,” according to its listing in the European Patent Register. Opposers to the patent include BioNTech and Pfizer, as well as Sanofi, the listing notes.
BioNTech “understands and welcomes” the EPO’s decision, a spokesperson said in an emailed statement. According to BioNTech, none of the more than 100 auxiliary requests that Moderna filed with amended claims were deemed sufficient to keep the patent in an amended form.
The decision “is an important one as we believe that this and others of Moderna’s patents do not meet the requirements for grant and should never have been granted,” the company added.
Meanwhile, Moderna “disagrees” with the EPO’s decision, a spokesperson told Fierce Pharma over email. “We continue to believe in the strength and validity of the ’565 Patent and will appeal this decision.”
Last year, Moderna initiated litigation against BioNTech and Pfizer in the U.S. and Germany, following up with cases in the Netherlands and the U.K. Most recently, the company filed suits in Dublin, Ireland and the Brussels Commercial Court Belgium.
Moderna has made it clear that its litigation doesn’t aim to remove Pfizer and BioNTech’s Comirnaty from the market, but instead reap compensation and damages from alleged infringement.
While Moderna claims Pfizer and BioNTech copied key features of its patented technologies, the rival partners have said the mRNA specialist seeks to rewrite the COVID story to put itself in the “single, starring role” while stretching its “already overbroad” patents to “claim credit for others’ work.”
PackGene Biotech is a world-leading CRO and CDMO, excelling in AAV vectors, mRNA, plasmid DNA, and lentiviral vector solutions. Our comprehensive offerings span from vector design and construction to AAV, lentivirus, and mRNA services. With a sharp focus on early-stage drug discovery, preclinical development, and cell and gene therapy trials, we deliver cost-effective, dependable, and scalable production solutions. Leveraging our groundbreaking π-alpha 293 AAV high-yield platform, we amplify AAV production by up to 10-fold, yielding up to 1e+17vg per batch to meet diverse commercial and clinical project needs. Moreover, our tailored mRNA and LNP products and services cater to every stage of drug and vaccine development, from research to GMP production, providing a seamless, end-to-end solution.
Related News
Sangamo Therapeutics Secures Accelerated Approval Pathway for Gene Therapy in Fabry Disease
Sangamo Therapeutics has announced a major advancement in its gene therapy program for Fabry disease, as the U.S. FDA has provided a clear pathway for Accelerated Approval. This decision could potentially speed up approval timelines by three years, with a Biologics...
[2024/10/18] Gene and Cell Therapy- weekly digest from PackGene
FeaturedNewsArticlesPackGene's NewsletterReceive the latest news and insights to your inbox.About PackGenePackGene Biotech is a world-leading CRO and CDMO, excelling in AAV vectors, mRNA, plasmid DNA, and lentiviral vector solutions. Our comprehensive offerings span...
GSK sues Moderna over mRNA vaccine patents, seeks ‘reasonable royalty’
GSK on Tuesday unveiled a lawsuit filed against Moderna in Delaware federal court, alleging that its patented inventions provide the “foundation” for Moderna’s mRNA vaccine portfolio. GSK said it’s looking to recover “a reasonable royalty” for Moderna’s tens of...
Gene Therapy Automatically Converts Omega-6 to Omega-3 Fatty Acids in the Body
Shriners Children's Develops New Technology to Prevent Childhood Obesity ST. LOUIS, Oct. 16, 2024 /PRNewswire/ -- According to the Centers for Disease Control, nearly 20% of children and teens are considered obese. Research shows it can have a dramatic impact on a...
Related Services